• Active Biotech reported the first patient dosed in the amended Phase Ib/II HO172 tasquinimod trial in myelofibrosis.
• Protocol changes increase dosing flexibility, aiming to improve patient management and trial execution.
• Study targets patients refractory to, or ineligible for, JAK2 inhibitors; tasquinimod is evaluated as monotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Active Biotech AB published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.